

Empowering Heart Health with Dual Action



In Hypertension with CAD/Post MI & Heart Failure

Rx **Affobis® T $\frac{2.5}{5}$**

Bisoprolol Fumarate 2.5/ 5 mg + Telmisartan 40 mg Tablets





Background:

The combination of Angiotensin Receptor Blockers (ARBs) and Beta-blockers has been proven effective in reducing cardiovascular events, particularly in patients with left ventricular hypertrophy, coronary artery disease (CAD), and heart failure. Clinical evidence highlights that the combined use of an ARB and a Beta-blocker leads to superior cardiovascular survival outcomes compared to monotherapy or other antihypertensive treatments. This combination therapy results in the lowest risk of cardiovascular and overall mortality, due to the synergistic actions of each medication. By utilizing the strengths of both drug classes, patients can benefit from enhanced therapeutic effects.

Available Strengths

- ✓ Bisoprolol 2.5 + Telmisartan 40 mg Tablets
- ✓ Bisoprolol 5 mg + Telmisartan 40 mg Tablets

Indication:

Affobis T is indicated in hypertension with Coronary Artery Disease (CAD) / Post MI & Heart Failure.

Mechanism of Action:

- ✓ Telmisartan works by inhibiting the action of angiotensin II, blocking its binding to the AT1 receptor, and thus reducing vasoconstriction and aldosterone release in key tissues such as blood vessels and the adrenal glands.
- ✓ Bisoprolol, a highly selective beta-1 blocker, primarily affects the heart by lowering heart rate and reducing blood pressure, ultimately improving cardiovascular stability and reducing strain on the heart.

Dosage:

Affobis T: Take 1-2 tablets daily, or as prescribed by the doctor.

Unique Selling Points (USP):

Bisoprolol:

- ✓ Offers higher beta-1 selectivity and a longer half-life compared to metoprolol.
- ✓ Demonstrates survival benefits in patients with heart failure.
- ✓ Provides superior heart rate reduction and comparable blood pressure control versus metoprolol.
- ✓ Significantly lowers all-cause mortality rates.

Telmisartan:


- ✓ Extended half-life for prolonged effect.
- ✓ Provides continuous, 24-hour blood pressure management.
- ✓ Delivers cardiovascular protection with improved patient tolerance.
- ✓ Effective in managing the progression of metabolic syndrome.



Corp. & Regd. Office:

1009-1010, Chiranjiv Tower, 43, Nehru Place, New Delhi - 110019 Tel.: 011-47589500-51(50 lines)

Web: www.medicamen.com/lifesciences | E-mail: info@medicamenlifesciences.com



2025 All rights reserved, Medicamen Lifesciences Pvt Ltd